JinmuYao Medical Technology Secures Tens of Millions in New Funding to Advance Comprehensive Solutions for Complex Intravascular Lesions

VCBeat has learned that Chinese innovative medical device company JIA MU YAO Medical Technology has announced the completion of a new round of financing amounting to tens of millions of yuan. This round received high recognition and strong support from multiple professional investment institutions, led by Hongsheng Capital and Yuan Sheng Venture Capital, with Haimaide Venture Capital participating as a co-investor. Following the completion of this financing, the company will accelerate the clinical trials and regulatory registration for its shockwave therapy system, while simultaneously advancing R&D, animal studies, and type testing for multiple new products.

Shanghai JIA MU YAO Medical Technology Co., Ltd. was established in March 2021. Its founding team boasts over 15 years of experience in the development of Class III implantable medical devices, with backgrounds from renowned domestic and international companies such as Medtronic, MicroPort, and Dräger. The company is dedicated to building an energy-based platform providing comprehensive solutions for complex endovascular lesions. It has successfully established its foundational technology and industrialization platforms, achieving independent research, development, and strategic deployment of core technologies, including mechanical, electrical, and software architectures, as well as complex algorithms. In 2023, JIA MU YAO made significant progress with its shockwave therapy system, completing clinical trial follow-ups, accelerating product registration efforts, and advancing pre-commercialization layouts.

Independent innovation is the core driving force behind JIA MU YAO’s rapid development. Over the past two years, the company has overcome key technological barriers in shockwave therapy systems, achieving high-precision and high-efficiency translation of these systems into clinical applications. The safety and efficacy of its products have been validated through human clinical trials, with their outstanding performance receiving high acclaim from numerous leading clinical experts both domestically and internationally. Leveraging its strengths in independent innovation, industrial translation capabilities, and future growth potential, JIA MU YAO has earned multiple honors, including “Yangpu Talent Show Belt Entrepreneurship Star,” “VB-Link Future Healthcare Innovation Solution,” and the “Bronze Award at the Yangtze River Delta Ju Jin Sci-Tech Innovation Competition,” garnering widespread recognition from all sectors of society.

Li Lifu, Founder of JIA MU YAO MedicalStatement: We extend our heartfelt gratitude to all shareholders for their profound trust and support in JIA MU YAO, and we thank every member of the JIA MU YAO team for their relentless pursuit of and commitment to innovation in medical devices. JIA MU YAO is dedicated to building an energy platform that provides comprehensive solutions for complex endovascular lesions. We remain closely attuned to clinical needs and translational medicine, persist in independent R&D and innovation, and establish an energy platform with core competitiveness. Over the past two years, we have witnessed the growth of our team and the remarkable leap of our products—from 0 to 1, from 1 to 60, and then from 60 to 90. Looking ahead, JIA MU YAO will continue to focus on tackling key innovative challenges, accelerating the R&D, clinical trials, and commercial launch of new products, thereby providing patients and physicians with a safer, more effective, and more convenient comprehensive solution for complex lesions. “No innovation, no future.” In the current wave of global technological advancement, only by staying true to our original aspiration and sustaining innovation can we go further. JIA MU YAO remains steadfast in its commitment to independent innovation and self-driven development, continuously overcoming difficulties to share China’s high-end medical technology with healthcare providers and patients alike.

Mr. Jiang Houjia, Founding Partner of Hongsheng CapitalJIA MU YAO is an energy platform company dedicated to providing comprehensive solutions for complex endovascular lesions. We highly appreciate JIA MU YAO’s “begin with the end in mind” commercialization strategy and are delighted that its product R&D progress is at the forefront in China. Hongsheng Capital will leverage its ecosystem resources to help JIA MU YAO continuously innovate in the field of vascular intervention, benefiting more patients. Finally, we are honored to co-lead this round of financing together with the Yuan Sheng Venture Capital team, and we thank Haimaide and other colleagues for their support in this financing effort.

Dr. Cheng Gang, Partner at Yuansheng Venture CapitalJIA MU YAO is committed to addressing complex cardiovascular lesions, which are internationally recognized as significant clinical challenges and represent a vast market opportunity. The company emphasizes the independent development of foundational technologies while actively establishing strategic collaborations in clinical settings and across the upstream and downstream value chain. Yuansheng Venture Capital remains confident in JIA MU YAO’s team capabilities in productization and commercialization. We are pleased to become a shareholder of JIA MU YAO and support the company’s growth and development.

Zhang Jie, Partner at VCBeat VenturesStatement: We have been closely monitoring the shockwave balloon segment. Foreign products, represented by Shockwave, have already validated the safety and efficacy of shockwave balloon technology in treating vascular calcification. The JIA MU YAO team completed the clinical trial for one product within just two years, demonstrating the cohesion and execution capability of its R&D team. In the future, Haimaide will continue to leverage its platform resources to empower the company and facilitate the rapid development and market launch of new product pipelines.

Hongsheng Capital focuses on equity investments in the healthcare and medical industry, with total assets under management exceeding RMB 1 billion. Its limited partners include more than ten publicly listed companies in the medical industry, state-owned enterprises, and market-oriented fund-of-funds. The management team consists of professional leaders from top-tier central state-owned pharmaceutical distribution companies, private equity funds, and publicly listed healthcare companies. Hongsheng Capital distinguishes itself through its “ecosystem investment strategy” and “comprehensive post-investment value-added services.” It leverages the advantageous resources of industrial listed companies and its team to build a healthcare ecosystem, while making deep investment allocations closely aligned with ecosystem resources.

Yuansheng Venture Capital is an investment firm focused on early- and growth-stage healthcare companies, headquartered in Suzhou BioBAY with a global reach. To date, it has invested in over 170 outstanding life sciences and healthcare enterprises, spanning four key sectors: novel drug development, medical devices, in vitro diagnostics and precision medicine, and healthcare services. The firm has achieved substantial investment returns, with 19 of its portfolio companies having gone public on capital markets such as the Hong Kong Stock Exchange and the STAR Market. Yuansheng Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investors in the country. By bringing together seasoned professional investors and a world-class team of scientific advisors, the firm possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and rich industry resources, Yuansheng Venture Capital is committed to becoming one of the most successful healthcare venture capital funds in China.

HiMed Venture Capital, established in 2015 and leveraging the HiMed Medical Innovation Acceleration Platform, focuses on early-stage investments in the healthcare sector. Many of the fund’s partners possess successful entrepreneurial experience and extensive industry resources, with deep expertise in healthcare collaboration, technology transfer, incubation, and investment. The firm currently manages two funds and has successfully invested in nearly 30 early-stage healthcare startups.